CJC-1295 DAC + Ipamorelin 2+5 mg
Dual-compound research stack combining long-acting CJC-1295 DAC and selective secretagogue Ipamorelin to investigate sustained GH axis amplification.
Mechanism
CJC-1295 DAC delivers prolonged pituitary GHRH receptor stimulation via albumin conjugation while Ipamorelin selectively activates GHS-R1a to trigger discrete growth hormone pulses.
Dosing
Standard research protocols evaluate a starting dose of 1 mg weekly for CJC-1295 DAC alongside daily 300 mcg administrations of Ipamorelin using dedicated syringes.
Reconstitution
Reconstitute the 2 mg CJC-1295 DAC vial with 1.0 mL bacteriostatic water to achieve 2 mg/mL, and the 5 mg Ipamorelin vial with 2.0 mL bacteriostatic water to yield 2.5 mg/mL.
Storage
Store both reconstituted vials refrigerated at 2–8 °C protected from light, avoid freezing, and utilize within 30 days.
Mix & measure CJC-1295 DAC + Ipamorelin 2+5 mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure CJC-1295 DAC + Ipamorelin 2+5 mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 7.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| CJC-1295 DAC (Standard) | 1 mg 1× per week | ~0.5 mL (50 units) |
| CJC-1295 DAC (Aggressive) | 2 mg 1× per week | ~1.0 mL (100 units) |
| Ipamorelin (Standard) | 300 mcg 1× daily | ~0.12 mL (12 units) |
Reconstitution Steps
- 1
Sanitize the stoppers of both lyophilized vials and the bacteriostatic water vial using sterile alcohol swabs and allow them to air-dry completely.
- 2
Draw 1.0 mL of bacteriostatic water into a sterile syringe and slowly introduce it along the inner glass wall of the 2 mg CJC-1295 DAC vial.
- 3
Draw 2.0 mL of bacteriostatic water and dispense it gently against the interior wall of the 5 mg Ipamorelin vial to prevent peptide damage.
- 4
Swirl both vials with smooth circular motions without vigorous agitation or shaking until the lyophilized powders fully dissolve.
- 5
Label each vial clearly with the reconstitution date and place both into cold storage at 2–8 °C protected from ambient light.
- 6
Draw individual aliquots for each peptide using dedicated, separate U-100 insulin syringes for experimental administration.
Supplies Needed
Peptide Vial
Lyophilized CJC-1295 DAC (2 mg) and Ipamorelin (5 mg) research materials.
Insulin Syringes (U-100)
Dedicated sterile syringes required for individual peptide measurement and administration.
Bacteriostatic Water
Sterile diluent used to reconstitute both individual peptide vials.
Alcohol Swabs
Sanitization of rubber septums and test preparation areas to ensure sterile technique.
Why researchers study it
GH & IGF-1 support
Fat metabolism / lipolysis
Body composition / lean mass
Sleep & recovery
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
The CJC-1295 DAC and Ipamorelin dual protocol pairs two distinct growth hormone secretagogues to evaluate complementary somatotropic signaling. CJC-1295 DAC represents a modified growth hormone-releasing hormone analog engineered with a drug affinity complex, enabling prolonged covalent binding to endogenous serum albumin. In contrast, Ipamorelin is a synthetic pentapeptide that selectively stimulates the ghrelin receptor without provoking non-specific increases in cortisol or prolactin secretion. Investigators explore this specific pairing to observe whether combining basal, sustained GHRH agonism with acute, pulsatile ghrelin-receptor triggering generates greater cumulative growth hormone and downstream IGF-1 outputs than monotherapy models. Because each agent utilizes separate endocrine pathways, the stack is heavily evaluated in metabolic, body composition, and tissue preservation models. Protocols require handling each peptide as a distinct entity in separate vials. Due to divergent pharmacokinetic half-lives and chemical stabilities, compounds are reconstituted and injected independently using individual sterile syringes to maintain analytical accuracy and prevent intermolecular degradation.
References
- 1.Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006 — Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults
- 2.Raun et al., European Journal of Endocrinology, 1998 — Ipamorelin, the first selective growth hormone secretagogue, with minimal effect on cortisol and prolactin
- 3.Smith et al., Endocrine Reviews, 1997 — Growth hormone secretagogues: mechanisms of action and clinical applications
- 4.Van Cauter et al., Sleep Medicine Reviews, 2007 — Sleep and the GH/IGF-1 axis: physiological and clinical implications
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allBiotinoyl Tripeptide-1 2-6 ppm
Topical biotin-conjugated tripeptide researched for follicular anchorage, keratinocyte proliferation, and cosmetic hair retention models.
View ProtocolCJC-1295 + Ipamorelin 10mg Blend
Dual-pathway growth hormone secretagogue blend pairing a synthetic GHRH analog with a selective ghrelin receptor agonist.
View ProtocolHGH Fragment 176-191 5mg
A truncated C-terminal human growth hormone peptide investigated in laboratory settings for lipolytic signaling without glycemic perturbation.
View Protocol